# Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

> **NCT00003296** · PHASE2 · UNKNOWN · sponsor: **Brown University** · enrollment: 26 (estimated)

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Liver Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00003296
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003296, "Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00003296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*